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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: The aim of this study was to investigate the cefoperazone
esulbactam (CFPeSUL) susceptibilities of important Gram-negative bacteria (GNB) by agar
dilution (reference method), disk diffusion, and two automated methods.
Methods: A total of 799 GNB isolates, including Enterobacteriaceae (nZ 500) and nonfermen-
tative GNB (NFGNB, nZ 299), were recovered from various clinical specimens collected at Na-
tional Taiwan University Hospital, Taipei, Taiwan from November 2013 to December 2014. The
agar dilution method, disk diffusion method, and two automated susceptibility systems
(Phoenix and Vitek 2) were used for testing susceptibility of the isolates to CFPeSUL.of Laboratory Medicine, National Taiwan University Hospital, Number 7, Chung-Shan South Road,
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azoneesulbactam, Journal of MicrobCategories of susceptibility (susceptible, intermediate, or resistant) to CFPeSUL yielded from
each method were interpreted according to CFPeSUL interpretive breakpoints proposed pre-
viously. The results of categorical agreement and errors obtained between the agar dilution
method and the other three methods were analyzed.
Results: The Vitek 2 system had the highest error rates against Escherichia coli (nZ 150) and
Enterobacter cloacae (nZ 77) isolates, i.e., 6.7% and 11.7% minor errors, 8.5% and 1.7% major
errors, and 40% and 20% very major errors, respectively. Additionally, the Vitek 2 system was
also found to have a significantly lower sensitivity (44.4%) and lower positive predictive value
(18.2%) for detecting CFPeSUL nonsusceptible E. coli isolates than other methods. For
carbapenem-nonsusceptible Enterobacteriaceae isolates, the Vitek 2 system failed to detect
correct susceptibility to CFPeSUL. The three methods failed to correctly detect CFPeSUL sus-
ceptibility categories against all NFGNB isolates except Pseudomonas aeruginosa.
Conclusion: The Vitek 2 system is a suboptimal method in correctly detecting CFPeSUL suscep-
tibility categories for E. coli, E. cloacae, and carbapenem-nonsusceptible Enterobacteriaceae
isolates.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Antimicrobial drug resistance is a serious health care
problem worldwide, and nosocomial infections due to
multidrug-resistant (MDR) Gram-negative bacilli (GNB) are
of particular concern.1,2 Initiation of appropriate antibi-
otics for treatment of severe infections, however, depends
on the rapid identification of the pathogen and an under-
standing of the susceptibility profiles of pathogens to
various antimicrobials.
Resistance to major antibiotics is often conferred by the
expression of b-lacatmases.2,3 Sulbactam (SUL), an impor-
tant b-lactamase inhibitor, was noted to possess good ac-
tivity against some extended-spectrum b-lactamase (ESBL)-
producing pathogens.4 Furthermore, this agent has been
shown to augment the activity of cefoperazone (CFP)
against a variety of Enterobacteriaceae species (especially
Escherichia coli, Morganella morganii, and Klebsiella
pneumoniae) which include some AmpC b-lactamase pro-
ducers as well (Enterobacter cloacae, Enterobacter aero-
genes, and Citrobacter freundii),5e7 and some important
nonfermentative GNB species that are originally resistant to
CFP.7e11
There are no recently validated minimum inhibitory
concentration (MIC) interpretive breakpoints for CFP
(with or without SUL) against GNB isolates by the Clinical
and Laboratory Standards Institute (CLSI) and the Euro-
pean Committee on Antimicrobial Susceptibility
Testing.12e14 CFP itself has fallen into disuse in the
United States (US) and European Union and CFPeSUL had
never been licensed in the US or anywhere in Western
Europe. However, this combination agent is still exten-
sively used in many hospitals of the Asian countries and
has been reported to successfully treat several nosoco-
mial infections, including mild-to-moderate nosocomial
pneumonia, intra-abdominal infections, and sepsis in
patients with febrile neutropenia.11,15,16 Nevertheless,
there were only a few studies comparing the accuracy of
various susceptibility testing methods for detection ofJean S-S, et al., Comparison of
cal isolates of Enterobacteriac
iology, Immunology and Infectionin vitro susceptibility of important GNB species to CFP or
CFPeSUL.5,6,17,18
In this study, we conducted an in vitro study to inves-
tigate the performance of the agar dilution method, disk
diffusion method, automated BD Phoenix (Becton Dick-
inson, Sparks, MD, USA), and Vitek 2 (bioMe´rieux, Marcy
l’Etoile, France) systems for evaluating susceptibility of
clinically important GNB isolates to CFPeSUL. Correlations
between the susceptibility profiles obtained by the agar
dilution method and the other three methods were also
explored.Methods
Bacterial isolates
From November 2013 to December 2014, a total of 799
non-duplicate GNB isolates (1 isolate per patient) were
randomly collected from various clinical specimens of
patients who were hospitalized at National Taiwan Uni-
versity Hospital, Taipei, Taiwan, a 2500-bed university-
affiliated tertiary care hospital. This study was approved
by the Institutional Review Boards of the National Taiwan
University Hospital (NTUH 201307067RINA). The GNB iso-
lates comprised Enterobacteriaceae species, namely E.
coli (n Z 150), K. pneumoniae (n Z 150), E. cloacae
(n Z 77), C. freundii (n Z 13), Serratia marcescens
(n Z 30), Salmonella species (n Z 50), Proteus mirabilis
(n Z 30), and nonfermentative GNB (NFGNB) species,
namely Pseudomonas aeruginosa (n Z 110), Acineto-
bacter calcoaceticuseAcinetobacter baumannii (Acb)
complex (n Z 120), Stenotrophomonas maltophilia
(n Z 39), Chyrseobacterium indologenes (n Z 10), Eliz-
abethkingia meningoseptica (n Z 12), and Burkholderia
cepacia complex (n Z 8). The isolates were identified
using conventional identification methods as well as the
Phoenix PMIC/ID-30 identification system (Becton
Dickinson).commonly used antimicrobial susceptibility testing methods for
eae and nonfermentative Gram-negative bacilli to cefoper-
(2015), http://dx.doi.org/10.1016/j.jmii.2015.08.024
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Antimicrobial susceptibilities of all isolates were deter-
mined concomitantly by the agar dilution, disk diffusion
method, and two commercial automated susceptibility
systems, namely the Phoenix system (Becton Dickinson) and
the Vitek 2 system (bioMe´rieux). The disks (75 mg CFP and
30 mg SUL) used in the disk diffusion method were obtained
from Becton Dickinson. For susceptibility testing by the
agar dilution method, CFPeSUL at a fixed 2:1 ratio of
CFP:SUL and serial two-fold CFP concentrations ranging
from 0.015 mg/mL to 128 mg/mL in combination with SUL
were used together with cation-adjusted Mueller-Hinton
agar (Becton Dickinson). The inoculated agar plates were
incubated in ambient air at 35C for 16e20 hours. The MIC
of each antimicrobial agent was defined as the lowest
concentration that inhibited visible growth of the organism.
For evaluation of the two automated susceptibility sys-
tems, a Vitek AST-N310 card (bioMe´rieux) and a BD Phoenix
Gram Negative Combo Panel (NMIC/ID-99; Becton Dickinson
Diagnostics) were used. For the Vitek AST-N310 card, the
ratio of concentration of CFP to SUL was 2:1 and the con-
centrations of CFP tested were  8 mg/mL, 16 mg/mL,
32 mg/mL, and  64 mg/mL. By contrast, with regard to the
Phoenix NMIC/ID99 panel, as Barry and Jones5 demon-
strated that the 8 mg/mL SUL concentration addition would
convert more CFP-nonsusceptible (MIC > 16 mg/mL) isolates
of Enterobacteriaceae and Pseudomonas spp. into CFP-
susceptible ones than the 4 mg/mL SUL concentration use,
the CFP concentrations were also tested in serial two-fold
dilutions ranging from 0.5 mg/mL to 32 mg/mL in combina-
tion with a fixed SUL concentration of 8 mg/mL. Control
strains of E. coli ATCC 25922, E. coli ATCC 35218, and P.
aeruginosa ATCC 27853, were included in each set of tests.
Tests were repeated for isolates showing discrepant re-
sults between the agar dilution and the other three evalu-
ated methods. If the results yielded by the initial and
repeated tests were not identical, all of the susceptibility
methods were repeated. The susceptibility results which
were obtained two out of three times were recorded as the
final results.
In this study we also investigated the susceptibilities of
all isolates to imipenem and meropenem by the agar dilu-
tion method to delineate carbapenem susceptibility.13Interpretation of susceptibility results
There are no CLSI-recommended MIC or disk diffusion
interpretive criteria for susceptibility of Enter-
obacteriaceae spp., P. aeruginosa, species of Acb complex,
B. cepacia complex, S. maltophilia and other non-Enter-
obacteriaceae isolates to CFPeSUL.13 Furthermore, these
MIC judgment criteria were also not documented in the
expert rules of the Vitek AST-N310 card or Phoenix NMIC/
ID99 panel. Nevertheless, in this study, isolates were
considered susceptible, intermediate, or resistant to
CFPeSUL in accordance with the previous MIC breakpoints
of CFPeSUL recommended by Jones et al6 and Barry and
Jones,5 which are just consistent with the CLSI 2015
guidelines for Enterobacteriaceae spp.,13 and the CLSI 2010
guidelines for P. aeruginosa for CFP alone.12 For the diskPlease cite this article in press as: Jean S-S, et al., Comparison of
evaluating susceptibilities of clinical isolates of Enterobacteriac
azoneesulbactam, Journal of Microbiology, Immunology and Infection(CFP/SUL, 75/30 mg) diffusion method, the isolates with
zone diameters  21 mm were defined as susceptible; those
with diameters ranging from 16 mm to 20 mm were defined
as intermediate; and isolates with zone diameters  15 mm
were defined as resistant, as stated elsewhere.5,19 For the
three dilution methods, after SUL was added, isolates with
CFP MIC values  16 mg/mL were defined as susceptible;
those with a MIC value of 32 mg/mL were defined as inter-
mediate; and isolates with CFP MIC values  64 mg/mL were
defined as resistant. Isolates showing no susceptibility to
either imipenem or meropenem, as defined by the CLSI,
were considered nonsusceptible to carbapenems.13
Data analysis
The rates of accuracy (categorical agreement) of the three
evaluation modalities (disk diffusion, BD Phoenix system,
and Vitek 2 system) were examined using GNB isolates.
Using the results of the agar dilution method as the refer-
ence, we analyzed categorical agreement (CA) of the sus-
ceptibility (i.e., susceptible, intermediate, and resistant)
categories between the evaluation system and agar dilution
method. Errors were defined as follows: a minor error (mE)
indicated that the result was intermediate in one system
and susceptible or resistant in the other; a major error (ME)
indicated a false-resistant result; and a very major error
(VME) indicated a false-susceptible result. When calcu-
lating the rates of error, we applied the following de-
nominators in respective species for estimation: the
number of reference resistant isolates for the VME rate, the
number of reference susceptible isolates for the ME rate,
and the number of all reference isolates for the mE rate,
respectively.17 The acceptable intermethod error rates of
VME, ME, and mE is  1.5%,  3%, and  10%,
respectively.20
Statistical analysis
Categorical variables are expressed as percentages of total
isolates required for specific purposes in respective species,
and were compared between different systems by the Chi-
square test with Yate’s correction or Fisher’s exact test, as
appropriate. Continuous variables were compared using the
Student’s t test or ManneWhitney U test, depending on the
validity of the normality assumption. In addition, sensi-
tivity, specificity, positive predictive values (PPV), and
negative predictive values (NPV) were calculated to
compare the accuracy (i.e., degree of categorical agree-
ment) of the disk diffusion, Vitek 2, and Phoenix systems
with that of the reference method (agar dilution) in
detecting CFPeSUL nonsusceptibilities. Finally, because
only a few nonfermentative GNB isolates (C. indologenes,
E. meningoseptica) have CLSI 2015-defined CFP MIC
breakpoints,13 the discriminatory powers of the methods
under evaluation were surveyed only for Enter-
obacteriaceae species by estimating the area under the
receiver-operating characteristic (ROC) curve. In this way,
we were able to explore the differences in accuracy be-
tween the three comparator methods and the agar dilution
method for correctly classifying the tested strains of
enterobacterial GNB species with low CA rates (< 90%) intocommonly used antimicrobial susceptibility testing methods for
eae and nonfermentative Gram-negative bacilli to cefoper-
(2015), http://dx.doi.org/10.1016/j.jmii.2015.08.024
Table 1 The range of minimum inhibitory concentrations (MICs) and disk diffusion diameter (in millimeters), MIC50, MIC90
levels, and susceptibility profiles (percentages of susceptible, intermediate, and resistant categories) versus cefoper-
azoneesulbactam for Gram-negative bacteria, and their concordance and discordance between the susceptibility results
evaluated by the agar dilution method (reference data) and the disk diffusion method, the BD Phoenix system, as well as the
Vitek 2 system, respectively.
Species, results Range
(mg/mL)
MIC50
(mg/mL)
MIC90
(mg/mL)
Susceptibilities % of susceptibility results with:
S (%) I (%) R (%) CA mE ME VME
Escherichia coli (n Z 150)
Agar dilution 0.03e64 1 16 94 2.7 3.3
Disk diffusion (diameter, mm) 13e35 92.7 5.3 2 97.3* 2.7 0* 0
BD Phoenix 0.5/8e>32/8 0.5/8 4/8 94 1.3 4.7 97.3* 2.7 0* 0
Vitek 2 8e64 8 8 85.3 5.3 9.3 84*,a(1) 6.7 8.5*,b(1) 40
Klebsiella pneumoniae (n Z 150)
Agar dilution 0.12e>128 0.25 16 90.4 1.9 7.7
Disk diffusion (diameter, mm) 13e28 86.5 5.8 7.7 96.7 3.3 0 0
BD Phoenix 0.5/8e>32/8 0.5/8 32/8 88.5 1.9 9.6 96 3.3 0.7 0
Vitek 2 8e64 8 8 94.2 0 5.8 95.3 4 0 16.7
Enterobacter cloacae (n Z 77)
Agar dilution 0.03e128 0.5 64 76.6 10.4 13
Disk diffusion (diameter, mm) 11e40 76.6 20.8 2.6 84.4b(2) 15.6b(2) 0 0
BD Phoenix 0.5/8e>32/8 0.5/8 >32/8 76.6 3.9 19.5 87b(3) 11.7b(3) 0 10
Vitek 2 8e64 8 64 77.9 6.5 15.6 84.4 11.7b(4) 1.7 20
Citrobacter freundii (n Z 13)
Agar dilution 0.25e32 0.5 2 92.3 7.7 0
Disk diffusion (diameter, mm) 16e28 92.3 7.7 0 100 0 0 0
BD Phoenix 0.5/8e>32/8 0.5/8 0.5/8 92.3 0 7.7 92.3c(3) 7.7 0 0
Vitek 2 8e64 8 8 92.3 0 7.7 92.3 7.7 0 0
Serratia marcescens (n Z 30)
Agar dilution 0.5e32 2 16 96.7 3.3 0
Disk diffusion (diameter, mm) 18e26 86.7 13.3 0 90 10 0 0
BD Phoenix 0.5/8e>32/8 2/8 16/8 96.7 0 3.3 93.3 3.3 3.4 0
Vitek 2 8e32 8 8 96.7 3.3 0 100 0 0 0c(4)
Salmonella spp. (n Z 50)
Agar dilution 0.25e32 1 8 98 2 0
Disk diffusion (diameter, mm) 18e28 98 2 0 100 0 0 0
BD Phoenix 0.5/8e>32/8 0.5/8 1/8 98 0 2 98 2 0 0
Vitek 2 8e32 8 8 98 2 0 100b(5) 0 0 0c(4)
Proteus mirabilis (n Z 30)
Agar dilution 0.5e8 1 2 100 0 0
Disk diffusion (diameter, mm) 25e34 100 0 0 100* 0 0 0
BD Phoenix 0.5/8e>32/8 0.5/8 4/8 93.3 3.3 3.3 93.3* 3.3 3.3 0
Vitek 2 8 8 8 100 0 0 100* 0 0 0b(4)
Pseudomonas aeruginosa (n Z 110)
Agar dilution 2e128 8 64 80 13.6 6.4
Disk diffusion (diameter, mm) 12e29 82.7 6.4 10.9 92.7 7.3 0 0
BD Phoenix 4/8e>32/8 8/8 >32/8 80 7.3 12.7 94.5b(6) 5.5c(5) 0c(7) 0
Vitek 2 8e64 8 64 81.8 7.3 10.9 93.6b(7) 6.4c(6) 0 0c(8)
Species of Acinetobacter calcoaceticuseAcinetobacter baumannii complex (n Z 120)
Agar dilution 1e128 4 64 78.3 6.7 15
Disk diffusion (diameter, mm) 6e34 76.7 10 13.3 91.7* 8.3 0* 0*
BD Phoenix 0.5/8e>32/8 0.5/8 >32/8 67.5 1.7 30.8 79.2* 8.3 13.8* 11.1
Vitek 2 8e64 8 32 89.2 5.8 5 82.5* 12.5 0* 33.3*
Stenotrophomonas maltophilia (n Z 39)
Agar dilution 8e>128 64 >128 5.1 23.1 71.8
Disk diffusion (diameter, mm) 8e26 12.8 51.3 35.9 56.4* 43.6 0 0*
BD Phoenix 1/8e>32/8 >32/8 >32/8 30.8 15.4 53.8 53.8* 35.9 0 14.3*
Vitek 2 8e64 8 16 94.9 2.6 2.6 10.3* 25.6 0 89.3*
Other nonfermentative GNBa (n Z 30)
Agar dilution 4e>128 32 >128 46.7 36.7 16.7
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Table 1 (continued )
Species, results Range
(mg/mL)
MIC50
(mg/mL)
MIC90
(mg/mL)
Susceptibilities % of susceptibility results with:
S (%) I (%) R (%) CA mE ME VME
Disk diffusion (diameter, mm) 6e31 60 16.7 23.3 73.3* 26.7 0 0
BD Phoenix 0.5/8e>32/8 32/8 >32/8 26.7 26.7 46.7 40*,c(9) 50b(8) 21.4 0
Vitek 2 8e64 32 64 16.7 56.7 26.7 53.3c(10) 33.3b(9) 21.4b(10) 20
a Other nonfermentative GNB comprises Chyrseobacterium indologenes (n Z 10), Elizabethkingia meningoseptica (n Z 12), and
Burkholderia cepacia complex (n Z 8).
b Above average (for all Enterobacteriaceae isolates, with statistically significant differences): 1 5.0%, 2 4.8%, 3 4.4%, 4 5.2%, and 5
91.2%, (and for all nonfermentative GNB, also with statistically significant differences): 6 77.6%, 7 74.2%, 8 15.1%, 9 14.0%, and 10 1.5%.
c Below the average (for all Enterobacteriaceae isolates, with statistically significant differences): 1 91.2%, 2 95.2%, 3 94.8%, and 4
20.0%, (and for all nonfermentative GNB, also with statistically significant differences): 5 15.1%, 6 14.0%, 7 8.0%, 8 50.8%, 9 77.6%, and 10
74.2%.
CAZ categorical agreement; GNBZ Gram-negative bacteria; IZ intermediate; mEZ minor error; MEZ major error; MICZ minimum
inhibitory concentration; R Z resistant; S Z susceptible; VME Z very major. error.
*The difference of rates of CA, mE, ME as well as VME in CFPeSUL susceptibilities yielded between three methods under evaluation is
significant (p < 0.05) by statistical analysis.
Susceptibility of Enterobacteriaceae to CFPeSUL 5
+ MODELcategories of CFPeSUL susceptibility. The method was also
applied to test the discriminatory power of the suscepti-
bility systems against carbapenem-nonsusceptible (i.e.,
nonsusceptibility to either of the 2 carbapenem agents)
enteric GNB isolates. All statistical calculations were two-
tailed, and p < 0.05 was considered statistically signifi-
cant. All statistical analyses were performed using SPSS
software version 17.0 (SPSS Inc., Chicago, IL, USA).
Results
The comparisons of CFPeSUL susceptibility data,
and categorical agreement rates between the agar
dilution method and the other three in vitro
methods for respective GNB species
The MIC range, MIC50 and MIC90 values, range of disk
diffusion diameters, and susceptibility profiles of the GNB
isolates are presented in Table 1. Nonparametric statistical
analyses revealed that isolates of E. cloacae and Salmonella
species had significantly smaller disk diffusion diameters
than the other enteric GNB species isolates with the
exception of K. pneumoniae (data not shown). In addition,
CFPeSUL susceptibility evaluated by the Vitek 2 system had
much higher ME rates for E. coli isolates than the disk
diffusion method and the BD Phoenix system (p < 0.001).
The CA rates ranged from 84.0% to 100% for Enter-
obacteriaceae. Comparison of the results of antimicrobial
susceptibility testing (AST) to CFPeSUL obtained from the
agar dilution method with those from the other three
methods revealed high rates of categorical disagreement
for three enterobacterial species, i.e., 10.0% by disk
diffusion for S. marcescens, 13.0e15.6% by the three
evaluation methods for E. cloacae, and 16.0% by the Vitek 2
system for E. coli isolates. Furthermore, high mE rates were
obtained by the Vitek 2 system for E. coli, E. cloacae, and P.
aeruginosa isolates (6.7%, 11.7%, and 6.4%, respectively) as
well as by the disk diffusion test for S. marcescens isolates
(10%). The Vitek 2 system had a very high rate of VME for
isolates of E. coli, E. cloacae, and K. pneumoniae (40%,Please cite this article in press as: Jean S-S, et al., Comparison of
evaluating susceptibilities of clinical isolates of Enterobacteriac
azoneesulbactam, Journal of Microbiology, Immunology and Infection20%, and 16.7%, respectively; Table 1). Of note, great de-
viations (with statistically significant differences) from the
average values in CFPeSUL susceptibility results against
overall Enterobacteriaceae organisms were also seen in the
Vitek 2 system for E. coli and in the three comparator
methods for E. cloacae isolates (Table 1). By contrast with
the enterobacterial isolates, there were complex differ-
ences in the AST results in CA and in error rates between
the three comparator testing methods, and significant de-
viations from the overall averages of the organisms for
isolates of the nonfermentative GNB species with the
exception of P. aeruginosa. Nevertheless, the disk diffusion
test was reliable (i.e., CA rates >90%) for correctly cate-
gorizing CFPeSUL susceptibility for P. aeruginosa and spe-
cies of Acb complex (Table 1).Performance of detection of CFPeSUL
nonsusceptibility for three in vitro methods
Fisher’s exact test revealed no significant differences in
detecting CFPeSUL nonsusceptibility of C. freundii and
Salmonella species, and S. marcescens and P. mirabilis
isolates between the agar dilution method and the other
three methods. By contrast, significant differences were
found between the agar dilution method and disk diffusion
test [7.3% vs. 6.0%; p < 0.001, odds ratio (OR) 0.014, and
95% confidence interval (CI) 0.004e0.056], as well as the BD
Phoenix (7.3% vs. 6.0%; p < 0.001, OR 0.008, 95% CI
0.001e0.057) and Vitek 2 systems (7.3% vs. 14.7%;
p Z 0.027, OR 0.287, 95% CI 0.123e0.671) for E. coli iso-
lates. As demonstrated in Table 2, there were also promi-
nent differences in detecting CFPeSUL nonsusceptibility for
K. pneumoniae, E. cloacae, P. aeruginosa, and species of
Acb complex, as well as S. maltophilia and the other
miscellaneous nonfermentative GNB isolates between the
agar dilution method and the other three evaluation
systems.
The performance of the three comparator methods with
respect to susceptibility profiles (nonsusceptibility vs. sus-
ceptibility) of the isolates of respective GNB species,commonly used antimicrobial susceptibility testing methods for
eae and nonfermentative Gram-negative bacilli to cefoper-
(2015), http://dx.doi.org/10.1016/j.jmii.2015.08.024
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cies are illustrated in Table 3. The Vitek 2 evaluation sys-
tem had a significantly lower sensitivity (44.4%), PPV
(18.2%) and CA rate (84.7%) for clinical E. coli isolates than
the other two methods. The Vitek 2 system also had
markedly low sensitivity (45.5%) for K. pneumoniae iso-
lates. Moreover, the Vitek 2 system performed poorly
(sensitivity 65.9%, PPV 57.4%) for all isolates of the seven
Enterobacteriaceae species tested. Wide diversities were
found in all of the performance parameters of the different
testing methods for detecting CFPeSUL nonsusceptible
strains of nonfermentative GNB species other than P. aer-
uginosa (Table 3).
The ROC curve analysis of the capacity of Vitek 2
system to identify correct susceptibility categories
among different Enterobacteriaceae spp
The ROC curve analysis demonstrated that the Vitek 2
system had a significantly poorer discriminatory power to
detect the correct categories of susceptibility of E. coli
isolates [area under the ROC curve (AUC) 0.654; pZ 0.123,
95% CI 0.448e0.859] than those of isolates of E. cloacaeTable 2 Comparisons of the capacity to detect nonsusceptibili
ation methods and the agar dilution method (reference) against
Species, comparisons of the capacity of each method with the re
data in detecting the CFPeSUL nonsusceptible isolates
Escherichia coli (n Z 150)
Disk diffusion
BD Phoenix system
Vitek 2 system
Klebsiella pneumoniae (n Z 150)
Disk diffusion
BD Phoenix system
Vitek 2 system
Enterobacter cloacae (n Z 77)
Disk diffusion
BD Phoenix system
Vitek 2 system
Pseudomonas aeruginosa (n Z 110)
Disk diffusion
BD Phoenix system
Vitek 2 system
Species of Acinetobacter calcoaceticuseAcinetobacter baumanni
Disk diffusion
BD Phoenix system
Vitek 2 system
Stenotrophomonas maltophilia (n Z 39)
Disk diffusion
BD Phoenix system
Vitek 2 system
Other nonfermentative GNB (n Z 30)a
Disk diffusion
BD Phoenix system
Vitek 2 system
a Other nonfermentative GNB comprised Chyrseobacterium indolo
Burkholderia cepacia complex (n Z 8).
CFPeSUL Z cefoperazoneesulbactam; CI Z confidence interval; GNB
Please cite this article in press as: Jean S-S, et al., Comparison of
evaluating susceptibilities of clinical isolates of Enterobacteriac
azoneesulbactam, Journal of Microbiology, Immunology and Infection(AUC 0.903; p < 0.001, 95% CI 0.786e1.000) and overall
isolates of the seven Enterobacteriaceae species (AUC
0.808; p < 0.001, 95% CI 0.719e0.897; Figures 1Ae1C). In
addition, we identified a total of 20 enteric GNB isolates (C.
freundii, nZ 1; E. coli, nZ 4; K. pneumoniae, nZ 5; and
E. cloacae, n Z 10) with a carbapenem-nonsusceptible
phenotype. The performance of Vitek 2 system was much
poorer than the disk diffusion and BD Phoenix methods in
correctly classifying CFPeSUL susceptibility of these resis-
tant GNB isolates (AUC 0.756; p Z 0.076, 95% CI
0.513e0.999; figure not shown).Discussion
This study highlights three important points. First, the Vitek
2 system performed poorly in recognizing the correct cat-
egories of CFPeSUL susceptibility among E. coli isolates.
Second, the CFPeSUL susceptibility profiles obtained by the
three comparator methods are in conflict with those from
the agar dilution method for E. cloacae strains. Third, all
three methods performed poorly in their ability to correctly
categorize CFPeSUL susceptibility among thety to cefoperazoneesulbactam yielded from the three evalu-
Gram-negative bacteria (GNB).
ference p OR 95% CI
<0.001 0.014 0.004e0.056
<0.001 0.008 0.001e0.057
0.027 0.287 0.123e0.671
<0.001 0.029 0.011e0.076
<0.001 0.022 0.007e0.066
<0.001 0.041 0.019e0.091
<0.001 0.018 0.003e0.126
<0.001 0.018 0.003e0.126
<0.001 0.041 0.010e0.161
<0.001 0.033 0.011e0.100
<0.001 0.035 0.011e0.106
<0.001 0.023 0.006e0.092
i complex (n Z 120)
<0.001 0.033 0.011e0.101
<0.001 0.180 0.111e0.293
<0.001 0.121 0.073e0.202
0.013 0.600 0.293e1.227
0.089 0.833 0.647e1.073
>0.99 0.946 0.876e1.022
0.001 0.303 0.141e0.651
0.417 0.635 0.243e1.657
0.642 0.714 0.231e2.208
genes (n Z 10), Elizabethkingia meningoseptica (n Z 12), and
Z Gram-negative bacteria; OD Z odds ratio.
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Table 3 Comparisons of the cefoperazoneesulbactam susceptibility profiles (nonsusceptible vs. susceptible) obtained from
the three evaluation methods and the reference (agar dilution) test for various kinds of Gram-negative bacteria.
Species (n) No. of isolates: Results (%) for:
þ by both
tests
Method þ
and REF 
Method 
and REF þ
 by both
tests
Sensitivity Specificity PPV NPV Agreement
Escherichia coli (150)
Disk diffusion 9 2 0 139 100* 98.6 81.8* 100 98.7*
BD Phoenix 8 1 1 140 88.9* 99.3 88.9* 99.3 98.7*
Vitek 2 4 18 5 123 44.4* 87.2 18.2* 96.1 84.7*
Klebsiella pneumoniae (150)
Disk diffusion 11 3 0 136 100* 97.8 78.6 100 98.0
BD Phoenix 11 3 0 136 100* 97.8 78.6 100 98.0
Vitek 2 5 0 6 139 45.5* 100 100 95.7 96.0
Enterobacter cloacae (77)
Disk diffusion 17 1 1 58 94.4 98.3 94.4 98.3 97.4
BD Phoenix 17 1 1 58 94.4 98.3 94.4 98.3 97.4
Vitek 2 15 2 3 57 83.3 96.6 88.2 95.0 93.5
Citrobacter freundii (13)
Disk diffusion 1 0 0 12 100 100 100 100 100
BD Phoenix 1 0 0 12 100 100 100 100 100
Vitek 2 1 0 0 12 100 100 100 100 100
Serratia marcescens (30)
Disk diffusion 1 3 0 26 100 89.7 25 100 90
BD Phoenix 0 1 1 28 0 96.6 0 96.6 93.3
Vitek 2 1 0 0 29 100 100 100 100 100
Salmonella spp. (50)
Disk diffusion 1 0 0 49 100 100 100 100 100
BD Phoenix 1 0 0 49 100 100 100 100 100
Vitek 2 1 0 0 49 100 100 100 100 100
Proteus mirabilis (30)
Disk diffusion 0 0 0 30 ND 100 ND 100 100
BD Phoenix 0 2 0 28 ND 93.3 0 100 93.3
Vitek 2 0 0 0 30 ND 100 ND 100 100
Overall isolates of the 7 Enterobacteriaceae species (500)
Disk diffusion 40 9 1 450 97.6* 98* 81.6* 99.8 98*
BD Phoenix 38 8 3 451 92.7* 98.3* 82.6* 99.2 99.3*
Vitek 2 27 20 14 439 65.9* 95.6* 57.4* 96.9 93.2*
Pseudomonas aeruginosa (110)
Disk diffusion 19 3 0 88 100 96.7 86.4 100 97.3
BD Phoenix 18 3 1 88 94.7 96.7 85.7 98.9 96.4
Vitek 2 18 2 1 89 94.7 97.8 90 98.9 97.3
Species of Acinetobacter calcoaceticuseAcinetobacter baumannii complex (120)
Disk diffusion 26 3 1 90 96.3* 96.8* 89.7* 98.9* 96.7*
BD Phoenix 23 15 3 79 88.5* 84* 60.5* 96.3* 85*
Vitek 2 13 0 13 94 50* 100* 100* 87.9* 89.2*
Stenotrophomonas maltophilia (39)
Disk diffusion 34 3 0 2 100* 40 91.9 100* 92.3*
BD Phoenix 27 0 10 2 73* 100 100 16.7* 74.4*
Vitek 2 2 0 35 2 5.4* 100 100 5.7* 10.3*
Other nonfermentative GNB species (30)a
Disk diffusion 11 1 5 13 68.8 92.9* 91.7* 72.2 80
BD Phoenix 13 9 3 5 81.3 35.7* 59.1* 62.5 60
Vitek 2 14 11 2 3 87.5 21.4* 56* 60 56.7
Overall isolates of the nonfermentative GNB species (299)
Disk diffusion 90 10 6 193 93.8* 95.1* 90* 97* 94.6*
BD Phoenix 81 27 17 174 82.7* 86.6* 75* 91.1* 85.3*
Vitek 2 47 13 51 188 48* 93.5* 78.3* 78.7* 78.6*
a Other nonfermentative GNB (30) isolates comprised Chyrseobacterium indologenes (10), Elizabethkingia meningoseptica (12), and
Burkholderia cepacia complex (8).
GNBZ Gram-negative bacteria; NDZ not done; NPVZ negative predictive value; PPVZ positive predictive value; REFZ reference (in-
dicates the results of agar dilution);þZpositive result for predicting nonsusceptibility;Z negative result for excluding nonsusceptibility.
*The difference of performance in parameters between the method(s) under evaluation and the agar dilution method (reference test) is
significant (p < 0.05) by statistical analysis.
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For susceptibility testing by the broth microdilution
method (the results equivalent to those of the agar dilution
method recommended in CLSI), the CFPeSUL combination
regimen consisting of a fixed 2:1 concentration ratio had
been shown to maximize the spectrum of activity against
many GNB species, and best simulate the parenteral
formulation as well as the pharmacokinetics of this com-
bination regimen.5 Furthermore, Barry and Jones5 clearly
proved that the in vitro performance of these disks corre-
lated well with that of the broth microdilution CFPeSUL
(also at the 2:1 concentration ratio) susceptibility test thatFigure 1. The discriminatory power [area under the receiver-o
correctly identify categories of susceptibility (susceptible, interm
isolates of (A) Escherichia coli, (B) Enterobacter cloacae, and (C) o
characteristic.
Please cite this article in press as: Jean S-S, et al., Comparison of
evaluating susceptibilities of clinical isolates of Enterobacteriac
azoneesulbactam, Journal of Microbiology, Immunology and Infectionwas recommended and outlined elsewhere.6 Consequently,
despite the use of disks containing 75 mg CFP and 30 mg SUL
(close to 2:1 ratio) in susceptibility testing not being
justified by the CLSI,12,13 we adopted these disks to
determine the CFPeSUL susceptibility test against the
clinically important GNB isolates in this study.
Prior to this investigation, only one study had investi-
gated the abilities of various AST evaluation methods
against specific antibiotic agents for clinical heteroresistant
E. cloacae and A. baumannii isolates.21 To the best of our
knowledge, no other study has compared the performance
of the disk diffusion method with that of two commonly
used, commercially available automated susceptibilityperating-characteristic (ROC) curve] of the Vitek 2 system to
ediate, or resistant) to cefoperazoneesulbactam among the
verall Enterobacteriaceae species. ROC Z receiver-operating-
commonly used antimicrobial susceptibility testing methods for
eae and nonfermentative Gram-negative bacilli to cefoper-
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such a large collection of the clinically important GNB iso-
lates. Although the automated tests are relatively less
labor-intensive for yielding AST data than the disk diffusion
method, disk diffusion is still a convenient method for
obtaining AST results against antibiotic(s). As shown by
Hardy et al,19 resistance among Enterobacteriaceae species
to CFPeSUL, as also defined by the broth microdilution
method, was highly concordant (85%, 17/20) with that ob-
tained by disk diffusion testing.19 This concordant rate in
fact shows an insignificant contrast with the proportion of
isolates determined by the disk diffusion method to be
nonsusceptible to CFPeSUL in our study (97.6%, pZ 0.063).
We found that all three comparator methods performed
poorly in detecting nonsusceptible strains of non-
fermentative GNB species with the exception of P. aerugi-
nosa. In addition to the high ME rate (6.7%) yielded from the
BD Phoenix system in the study conducted by Juretschko
et al,22 Donay et al17 also found a strikingly lower CA rate
(70.6%) by the BD Phoenix system for P. aeruginosa isolates
against piperacillinetazobactam. By contrast, the CA rate
detected by the BD Phoenix system for P. aeruginosa iso-
lates against CFPeSUL (94.5%) in our survey was similar to
that also obtained from the BD Phoenix system against CFP
(96.6%) in the survey of Menozzi et al.18 Therefore, the BD
Phoenix system appears to be an accurate method for
testing susceptibility of P. aeruginosa isolates to CFPeSUL.
By comparison with the minimal performance re-
quirements recommended by the National Committee for
Clinical Laboratory Standards in 1994 and International
Organization for Standardization,20,23 we found that use of
the formula suggested by Menozzi et al18 for the Vitek 2
system resulted in significantly low CA rates (< 90%) as well
as disproportionately high error rates (mostly much higher
than 3.0%) for E. coli and E. cloacae isolates. Among the
tested organisms of those two species of the Enter-
obacteriaceae family, we found that the Vitek 2 system
showed a high number of minor errors among E. coli
(n Z 10), K. pneumoniae (n Z 6), and E. cloacae (n Z 9)
isolates and a high number of major errors among E. coli
(n Z 12) isolates. In addition, despite the E. coli isolates
accounting for only 30% of all Enterobacteriaceae isolates
in our survey, the high number (n Z 18) of false non-
susceptible E. coli strains detected by the Vitek 2 system
has a great impact on calculating the PPV for E. coli isolates
{< 20% [4/(4 þ 18)]} as well as for Enterobacteriaceae
isolates {< 60% [27/(27 þ 18þ2)]}, as seen in Table 3. By
contrast, although higher mE rates were also observed by
the disk diffusion method for E. cloacae and S. marcescens
(15.6% and 10%, respectively) than for other Enter-
obacteriaceae species, no VME or ME strain was found for
these two species.
The main drawback of this in vitro study is that the
resistance mechanisms of the GNB isolates analyzed against
b-lactam agents (especially b-lactamases) were not well
characterized. Of 220 E. coli and K. pneumoniae isolates
proven to be ESBL producers, Jang et al24 found that the
Vitek 2 system produced high rates of VME (27.4%) when
testing susceptibility to cefepime and an error rate of 4.5%
for ceftazidime compared to the reference data of broth
microdilution test. Lat et al25 also found that the Vitek 2
system resulted in high VME rates on the susceptibility of K.Please cite this article in press as: Jean S-S, et al., Comparison of
evaluating susceptibilities of clinical isolates of Enterobacteriac
azoneesulbactam, Journal of Microbiology, Immunology and Infectionpneumoniae carbapenemase-producing K. pneumoniae
strains to meropenem (27%) and cefepime (67%) when CLSI
2010-determined MIC breakpoints were applied.12,25 In
addition, a survey conducted by Pailhorie`s et al26, who
recently investigated 14 ertapenem-nonsusceptible E.
cloacae strains with potential ESBL production, observed
that nine (64.3%) strains with mE in categorical discordance
of susceptibility were detected from the Vitek 2 system
when compared to MIC data from the agar dilution test. In
our survey, the Vitek 2 method correspondingly showed the
poorest discriminatory ability in identifying the correct
CFPeSUL susceptibilities for carbapenem-nonsusceptible
enterobacterial strains among three comparator testing
methods. It remains to be investigated if the results of
susceptibility testing for MDR strains of some members of
the Enterobacteriaceae family against many b-lactam drugs
obtained from the Vitek 2 system agree well with those
obtained by the reference method. Additionally, the high
VME rates of the Vitek 2 system in our survey referred to the
very limited VME numbers (2 VMEs for E. coli and E. cloacae
and 1 for K. pneumoniae) that were divided by small isolate
numbers exhibiting a true CFPeSUL resistant phenotype (5
for E. coli, 6 for K. pneumoniae, and 10 for E. cloacae,
respectively) for these three species. If the number of total
isolates of respective species was used as a new denomi-
nator, significantly lower VME rates will be yielded (1.3% for
E. coli, 0.7% for K. pneumoniae, and 2.6% for E. cloacae,
respectively) than those in Table 1 of our survey. To avoid
considerable deviations in reestimating the VME rates,
more E. coli and E. cloacae strains proven with CFPeSUL
resistant susceptibility by the reference testing might be
needed. Finally, because the half-life of CFP differs
considerably from that of SUL,5 this impact regarding
in vitro CFPeSUL susceptibilities obtained by disk or any
automated method on its application for clinical manage-
ment is worth being investigated.
In conclusion, although the Vitek 2 system still has
acceptable accuracy in detecting the correct CFPeSUL
susceptibility categories for isolates of some Enter-
obacteriaceae species, we found it to be an unreliable
method for E. coli and E. cloacae. Furthermore, using the
interpretive criteria applied in our study, none of the three
tested methods are appropriate alternative means for
yielding data on susceptibility of nonfermentative GNB to
CFPeSUL with the exception of the disk diffusion method
for P. aeruginosa and species of Acb complex. As the
database of automated systems is updated, future studies
should be undertaken to explore the changes in AST results
obtained by these systems against CFPeSUL for important
GNB species.Conflicts of interest
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